


COMPLIANCE REPORT

It is hereby certified that the draft scheme of arrangement involving between **Suven Life Science Limited (“Demerged Company”)** and **Suven Pharmaceuticals Limited (“Resulting Company”)** does not, in any way violate, override or limit the provisions of securities laws or requirements of the Stock Exchange(s) and the same is in compliance with the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and **SEBI Circular no CFD/DIL3/CIR/2017/21 dated March 10, 2017 (“SEBI Scheme Circular”)**, including the following:

Sl. No	Reference	Particulars	Compliance status
1.	Regulations 17 to 27 of LODR Regulations	Corporate governance requirements	Complied
2.	Regulation 11 of LODR Regulations	Compliance with securities laws	Complied
Requirements with SEBI Scheme circular			
a)	Para (I)(A)(2)	Submission of documents to Stock Exchanges	Complied
b)	Para (I)(A)(2)	Conditions for schemes of arrangement involving unlisted entities	Complied
c)	Para (I)(A)(4)(a)	Submission of Valuation Report	Complied. Independent Auditor’s certificate attached.
d)	Para (I)(A)(5)	Auditors certificate regarding compliance with Accounting Standards	Complied
e)	Para (I)(A)(9)	Provision of approval of public shareholders through e-voting	Complied

For Suven Life Sciences Limited


K. Hanumantha Rao
 Company Secretary



For Suven Life Sciences Limited



Venkateswarlu Jasti
 Chairman and CEO

Suven Life Sciences Limited

Certified that the transactions/ accounting treatment provided in the draft Scheme of Arrangement between Suven Life Sciences Limited and Suven Pharmaceuticals Limited are in compliance with all the Accounting Standards applicable to a listed entity.

For Suven Life Sciences Limited


P. Subba Rao
Chief Financial Officer



For Suven Life Sciences Limited


Venkateswarlu Jasti
Chairman and CEO

Date: February 14, 2019